Quarterly report pursuant to Section 13 or 15(d)

Segment, Geographical and Other Revenue Information (Tables)

v3.21.1
Segment, Geographical and Other Revenue Information (Tables)
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Schedule of segment reporting
The following table provides financial information by our reportable business segments along with a reconciliation to consolidated income (loss) before income taxes (in thousands):
Three months ended March 31, 2021 Three months ended March 31, 2020
Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total
Revenues:
Product revenue $ 10,226  $ —  $ 10,226  $ 5,100  $ —  $ 5,100 
Research and development revenue 4,003  3,803  7,806  5,774  3,796  9,570 
Total revenues 14,229  3,803  18,032  10,874  3,796  14,670 
Costs and operating expenses:
Cost of product revenue 4,218  —  4,218  2,541  —  2,541 
Research and development(1)
6,444  4,605  11,049  5,696  4,925  10,621 
Selling, general and administrative(1)
2,818  600  3,418  2,345  591  2,936 
Total segment costs and operating expenses 13,480  5,205  18,685  10,582  5,516  16,098 
Income (loss) from operations $ 749  $ (1,402) (653) $ 292  $ (1,720) (1,428)
Corporate costs (2)
(7,728) (5,727)
Unallocated depreciation and amortization (685) (492)
Loss before income taxes $ (9,066) $ (7,647)
(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.
(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.
The following table provides stock-based compensation expense included in income (loss) from operations (in thousands):
Three months ended March 31,
2021 2020
Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total
Stock-based compensation $ 994  $ 238  $ 1,455  $ 2,687  $ 756  $ 241  $ 1,172  $ 2,169 
Schedule of customers that contributed 10% or more of total accounts receivable
Significant Customers
Customers that each accounted for 10% or more of our total revenues were as follows:
Percentage of Total Revenues for the
Three Months Ended March 31,
2021 2020
Customer A 28  % 24  %
Customer B * 19  %
Customer C 11  % 15  %
Customer D 10  % 11  %
Customer E 14  % *
* Percentage was less than 10%
Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:
Percentage of Accounts Receivables as of
March 31, 2021 December 31, 2020
Customer A 41  % 32  %
Customer B * 25  %
Customer D 11  % 13  %
Customer F 12  % *
Customer G 11  % *
* Percentage was less than 10%
Schedule of revenues by geographical area
Geographic revenues are identified by the location of the customer and consist of the following (in thousands):
  Three Months Ended March 31,
2021 2020
Revenues
Americas $ 4,929  $ 5,225 
EMEA 6,282  5,971 
APAC 6,821  3,474 
Total revenues $ 18,032  $ 14,670 
Schedule of long-lived assets by geographical area
Identifiable long-lived assets by location was as follows (in thousands):
March 31, 2021 December 31, 2020
United States $ 31,248  $ 31,176 
Schedule of intangible assets and goodwill
Identifiable goodwill by reporting unit was as follows (in thousands):
As of March 31, 2021 and December 31, 2020
Performance Enzymes Novel Biotherapeutics Total
Goodwill $ 2,463  $ 778  $ 3,241